永太科技(002326.SZ):磷酸西格列汀原料藥產品獲印度註冊證書
格隆匯3月31日丨永太科技(002326.SZ)公佈,公司子公司浙江永太藥業有限公司(“永太藥業”)於近日收到印度中央藥品標準管理局(Central Drugs Standard Control Organisation)衞生和家庭福利部(Ministry of Health & Family Welfare)關於原料藥磷酸西格列汀的註冊證書。
磷酸西格列汀是一種二肽基肽酶-4 (DPP-4)抑制劑,在2型糖尿病患者中可通過增加活性腸促胰島激素的水平而改善血糖控制。磷酸西格列汀原研公司為美國默沙東,最早於2006年10月獲得美國FDA的上市批准。
永太藥業此次磷酸西格列汀原料藥產品獲得印度註冊證書,標誌着該原料藥符合印度藥典的相關要求,可以在印度市場進行銷售,為公司進一步拓展國際市場帶來積極影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.